The approval was based on a study conducted on 95 pediatric and adult patients suffering from cystic fibrosis. Patients received TOBI Podhaler or placebo for the first 28 days of the study. After that ...

FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US - TOBI Podhaler is indicated for certain cystic fibrosis (CF) ...

The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes ...

TOBI Podhaler (tobramycin inhalation powder) 28mg capsules by Novartis Novartis' TOBI Podhaler, indicated for the management of cystic fibrosis in patients with Pseudomonas aeruginosa bacteria in the ...

Novartis Pharmaceuticals Corporation has received the US Food and Drug Administration (FDA) approval for TOBI Podhaler (tobramycin inhalation powder) 28 mg per capsule for the management of cystic ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. TOBI PODHALER contains the active ingredient tobramycin. TOBI PODHALER ...

Tobi (tobramycin) is a prescription drug used to help treat a specific type of infection in people who have cystic fibrosis. Tobi comes as a solution or powder that you inhale. Tobi contains the ...

Tobi and Tobi Podhaler (tobramycin) are typically used twice per day for 4-week cycles (4 weeks on, 4 weeks off). It’s important to take the Tobi dosage your doctor prescribes. Tobi (tobramycin) is a ...

Novartis receives EU approval recommendation for TOBI® Podhaler®, a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients CHMP supports approval of TOBI Podhaler, a ...

Tobramycin 28mg; per cap; dry pwd for oral inhalation; with Podhaler device. <6yrs: not established. For oral inhalation use only with Podhaler device; do not swallow caps. Give in alternate 28-day ...